Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
proNERVE RCT
NCT07832266Phase 1Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2027
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
Phase 1, randomised trial of prednisone and fremanezumab in cranial nerve injury (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
prednisonefremanezumab
03
Conditions
cranial nerve injury
Beyond the preview
Go deeper on NCT07832266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832266.